What is a stock summary page? Click here for an overview.
Business Description
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
BCTX: Ordinary Shares - NewDescription
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.39 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | 1.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 63.74 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.41 | |||||
| 9-Day RSI | 27.44 | |||||
| 14-Day RSI | 34.56 | |||||
| 3-1 Month Momentum % | 2.99 | |||||
| 6-1 Month Momentum % | -49.8 | |||||
| 12-1 Month Momentum % | -78.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.37 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 0.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -82.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -134.58 | |||||
| ROIC % | -1468.41 | |||||
| 3-Year ROIIC % | -1352.34 | |||||
| ROC (Joel Greenblatt) % | -4172.12 | |||||
| ROCE % | -877.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 2.45 | |||||
| EV-to-EBIT | -0.53 | |||||
| EV-to-Forward-EBIT | -0.43 | |||||
| EV-to-EBITDA | -0.53 | |||||
| EV-to-FCF | -0.66 | |||||
| Price-to-Net-Current-Asset-Value | 6 | |||||
| Earnings Yield (Greenblatt) % | -188.68 | |||||
| FCF Yield % | -110.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.03 | ||
| Beta | 1.66 | ||
| 3-Year Sharpe Ratio | -0.73 | ||
| 3-Year Sortino Ratio | -0.97 | ||
| Volatility % | 109.28 | ||
| 14-Day RSI | 34.56 | ||
| 14-Day ATR ($) | 0.480522 | ||
| 20-Day SMA ($) | 4.0175 | ||
| 12-1 Month Momentum % | -78.36 | ||
| 52-Week Range ($) | 2.814 - 29.399999 | ||
| Shares Outstanding (Mil) | 6.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BriaCell Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(BCTX)'s stock price today?
The current price of BCTX is $2.94. The 52 week high of BCTX is $29.40 and 52 week low is $2.81.
When is next earnings date of BriaCell Therapeutics Corp(BCTX)?
The next earnings date of BriaCell Therapeutics Corp(BCTX) is 2025-06-13 Est..
Does BriaCell Therapeutics Corp(BCTX) pay dividends? If so, how much?
BriaCell Therapeutics Corp(BCTX) does not pay dividend.
Guru Commentaries on NAS:BCTX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers